These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 24462919)

  • 1. New perspectives on the role of tau in Alzheimer's disease. Implications for therapy.
    Medina M; Avila J
    Biochem Pharmacol; 2014 Apr; 88(4):540-7. PubMed ID: 24462919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in tau-based therapeutics for neurodegenerative diseases.
    Medina M
    Recent Pat CNS Drug Discov; 2011 Jan; 6(1):20-30. PubMed ID: 21118095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Overview on the Clinical Development of Tau-Based Therapeutics.
    Medina M
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease.
    Madav Y; Wairkar S; Prabhakar B
    Brain Res Bull; 2019 Mar; 146():171-184. PubMed ID: 30634016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies.
    Clavaguera F; Grueninger F; Tolnay M
    Neuropharmacology; 2014 Jan; 76 Pt A():9-15. PubMed ID: 24050961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J; Levy M; Dickson DW; Potter H
    Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau Proteins and Tauopathies in Alzheimer's Disease.
    Chong FP; Ng KY; Koh RY; Chye SM
    Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of tau phosphorylation and cleavage in neuronal cell death.
    Chun W; Johnson GV
    Front Biosci; 2007 Jan; 12():733-56. PubMed ID: 17127334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tau story: from frontotemporal dementia to other tauopathies].
    Buée L; Hamdane M; Delobel P; Sambo AV; Bégard S; Ghestem A; Sergeant N; Delacourte A
    J Soc Biol; 2002; 196(1):103-8. PubMed ID: 12134624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies.
    Iqbal K; Grundke-Iqbal I
    Acta Neuropathol; 2005 Jan; 109(1):25-31. PubMed ID: 15645264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current strategies for the treatment of Alzheimer's disease and other tauopathies.
    Dickey CA; Petrucelli L
    Expert Opin Ther Targets; 2006 Oct; 10(5):665-76. PubMed ID: 16981824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neuropathological spectrum of neurodegenerative tauopathies.
    Tolnay M; Probst A
    IUBMB Life; 2003 Jun; 55(6):299-305. PubMed ID: 12938731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau phosphorylation in neuronal cell function and dysfunction.
    Johnson GV; Stoothoff WH
    J Cell Sci; 2004 Nov; 117(Pt 24):5721-9. PubMed ID: 15537830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau phosphorylation in Alzheimer's disease: pathogen or protector?
    Lee HG; Perry G; Moreira PI; Garrett MR; Liu Q; Zhu X; Takeda A; Nunomura A; Smith MA
    Trends Mol Med; 2005 Apr; 11(4):164-9. PubMed ID: 15823754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further understanding of tau phosphorylation: implications for therapy.
    Medina M; Avila J
    Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains.
    Feuillette S; Deramecourt V; Laquerriere A; Duyckaerts C; Delisle MB; Maurage CA; Blum D; Buée L; Frébourg T; Campion D; Lecourtois M
    Brain Res; 2010 Jul; 1345():182-9. PubMed ID: 20460118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The microtubule-associated protein tau in neurodegenerative diseases. Tauopathies].
    Sánchez MP; Alvarez-Tallada V; Avila J
    Rev Neurol; 2001 Jul 16-31; 33(2):169-77. PubMed ID: 11562878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.